Detalles de la búsqueda
1.
Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.
J Oncol Pharm Pract
; 29(4): 958-961, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36823960
2.
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.
Future Oncol
; 18(40): 4457-4464, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36946237
3.
Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
Clin Colorectal Cancer
; 23(1): 1-3, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37932152
4.
The screening with the liquid biopsy for the rechallenge with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer A perspective based on pharmacological costs.
Recenti Prog Med
; 114(9): 563-564, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37530025
5.
Analysis of risk factors for lymph nodal involvement in early stages of rectal cancer: when can local excision be considered an appropriate treatment? Systematic review and meta-analysis of the literature.
Int J Surg Oncol
; 2012: 438450, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22778940
Resultados
1 -
5
de 5
1
Próxima >
>>